Bacopa monnieri (Brahmi) is a classical Ayurvedic nootropic whose active compounds -- bacosides A and B -- enhance memory and cognitive function through acetylcholinesterase inhibition, serotonin modulation, and BDNF upregulation. Multiple double-blind RCTs in both healthy adults and elderly populations consistently demonstrate improvements in memory acquisition, retention, and cognitive processing speed, with a notable requirement of 8-12 weeks of continuous use before benefits manifest. Bacopa falls outside the European phytotherapy regulatory framework but is listed in the Ayurvedic Pharmacopoeia of India and the Australian TGA.

Black pepper (Piper nigrum) and its alkaloid piperine are used almost exclusively as bioavailability enhancers in modern phytotherapy and supplement practice, not as standalone therapeutics. The landmark finding is a 2000% increase in curcumin blood levels when 20 mg piperine is co-administered. Piperine achieves this through inhibition of P-glycoprotein, CYP3A4, CYP2D6, and glucuronidation enzymes (UGT). However, these same mechanisms create significant drug interaction potential -- piperine at 20 mg/day can increase AUC of simvastatin by 59%, cyclosporine by 35%, and carbamazepine by 48%. No formal herbal monograph exists from Commission E, ESCOP, or EMA for piperine as a bioavailability enhancer. Black pepper occupies a unique position as an adjuvant rather than a primary therapeutic agent.

Butterbur root extract (Petadolex) has some of the strongest clinical evidence of any herbal product for migraine prevention, with Class 1 RCTs showing 48-68% responder rates at 150 mg/day and a former AAN Level A recommendation. However, butterbur plants naturally contain hepatotoxic pyrrolizidine alkaloids (PAs). Although Petadolex is manufactured to be PA-free, reports of liver injury (whose causal relationship to butterbur is disputed) led to product withdrawal in Germany in 2009 and retirement of the AAN guideline. The herb represents a unique case where strong efficacy evidence collides with unresolved safety questions.

Cinnamon bark has an EMA traditional use monograph for mild GI symptoms (cramping, flatulence). Its use for blood glucose management in type 2 diabetes, while widely marketed, remains clinically inconclusive based on systematic reviews and meta-analyses. A critical distinction exists between cassia cinnamon (high coumarin, more studied for glucose) and Ceylon cinnamon (low coumarin, safer for long-term use but less studied). The European BfR and EFSA have set a tolerable daily intake of 0.1 mg coumarin/kg body weight, which cassia cinnamon can easily exceed.

Coleus forskohlii (syn. Plectranthus barbatus) is an Ayurvedic medicinal plant whose root contains forskolin, the only known natural compound that directly activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels. This universal second messenger mechanism gives forskolin remarkably broad pharmacological effects: bronchodilation, vasodilation, positive cardiac inotropy, lipolysis, reduced intraocular pressure, and anti-inflammatory activity. Clinically, ophthalmic forskolin for glaucoma has the strongest evidence; oral supplementation for body composition and weight management has modest RCT support. Forskolin eye drops are used in some countries as an alternative to beta-blockers for glaucoma. The oral extract (typically standardized to 10-20% forskolin) has shown modest benefits for body composition in small trials. No European regulatory monographs exist, though the plant is documented in the Ayurvedic Pharmacopoeia.

Fenugreek seed is one of the oldest medicinal plants, approved by Commission E for internal use (loss of appetite) and external use (local inflammation as poultice). The ESCOP monograph additionally includes adjuvant therapy in diabetes and mild hypercholesterolemia. The EMA/HMPC recognizes traditional use for appetite loss (internal) and mild skin inflammations (external). Clinical evidence for blood glucose reduction in type 2 diabetes is positive in meta-analyses (significant reductions in fasting glucose and HbA1c) but based largely on low-quality trials. A distinctive maple-syrup odor in sweat and urine is a harmless but notable side effect.

Ginger is one of the few herbal medicines to receive EMA "well-established use" classification -- for prevention of nausea and vomiting in motion sickness. This is the highest regulatory recognition in EU phytotherapy, supported by multiple RCTs and meta-analyses. Evidence for pregnancy-related nausea is positive but European regulatory bodies remain cautious (Commission E and ESCOP do not endorse this use). Post-operative nausea evidence is growing. Ginger's safety profile is excellent at recommended doses, making it one of the most evidence-based herbs in this module.

Gymnema sylvestre is a woody climbing vine from the Apocynaceae family, used for over 2,000 years in Ayurvedic medicine under the name "Meshashringi" (sugar destroyer) for glycosuria and metabolic disorders. Its primary bioactives, gymnemic acids I-VII, structurally resemble glucose and block sweet taste receptors on the tongue (T1R2/T1R3) while inhibiting intestinal glucose absorption. A 2021 systematic review and meta-analysis of 10 studies (n=419) found significant reductions in fasting blood glucose, postprandial glucose, and HbA1c in type 2 diabetes patients, though most trials were small, open-label, and of low-to-moderate methodological quality. Animal studies suggest possible pancreatic beta-cell regeneration, but this remains unconfirmed in humans. No European regulatory body (Commission E, ESCOP, or EMA) has issued a monograph for gymnema, limiting its formal recognition to the Indian Pharmacopoeia and Ayurvedic Pharmacopoeia of India.

Licorice root is one of the most important herbs in both European and Asian medicine, approved by Commission E and ESCOP for gastric/duodenal ulcers, gastritis, and respiratory catarrh. Its primary active compound glycyrrhizin (and its metabolite glycyrrhetinic acid) has potent anti-inflammatory and mucosal-protective effects but also causes mineralocorticoid-like adverse effects: sodium retention, potassium loss, and hypertension. This limits use to 4-6 weeks and a maximum glycyrrhizin intake of 100 mg/day. DGL (deglycyrrhizinated licorice) was developed to provide GI benefits without the hypertension risk and is effective for peptic ulcer symptoms when taken as chewable tablets.

Lion's Mane (Hericium erinaceus) is a medicinal mushroom with a long history of use in traditional Chinese and Japanese medicine, now attracting significant scientific interest for its unique neurotrophic properties. Its key bioactive compounds -- hericenones (from the fruiting body) and erinacines (from the mycelium) -- stimulate the synthesis of nerve growth factor (NGF), a mechanism distinct from all conventional nootropics. The landmark Mori et al. 2009 RCT demonstrated significant cognitive improvement in patients with mild cognitive impairment over 16 weeks, though benefits reversed upon discontinuation. Preclinical evidence for neuroprotection and remyelination is strong, but clinical trial data remains limited in both quantity and sample size. Lion's Mane falls outside the European phytotherapy regulatory framework.

European mistletoe is one of the most widely used complementary cancer therapies in German-speaking countries (~77% of oncology patients), administered as subcutaneous injections of standardized extracts (Iscador, Helixor, abnobaVISCUM). It contains immunomodulatory lectins and cytotoxic viscotoxins. Clinical evidence suggests improvements in quality of life and possible survival benefits, but the evidence base is methodologically contested. The US FDA has not approved mistletoe for any indication and prohibits its importation except for research. This is the single largest EU-US divergence in complementary medicine.

Panax ginseng (Korean ginseng) is one of the most extensively studied medicinal plants worldwide, with over 2,000 years of documented use in Traditional Chinese Medicine as the premier Qi tonic (Ren Shen). Its principal bioactive compounds, the ginsenosides (especially Rb1, Rg1, Rg3, Re, and Rd), act through multiple mechanisms including HPA axis modulation, nitric oxide synthesis, neuroprotection via BDNF/TrkB signaling, and immune cell activation. Clinical evidence from multiple RCTs and meta-analyses supports benefits for fatigue reduction, modest cognitive improvement (particularly memory), glycemic regulation in type 2 diabetes, and enhanced NK cell activity. The standardized extract G115 (4% ginsenosides) is the most extensively studied preparation. Panax ginseng holds Commission E and ESCOP approval as a tonic for fatigue and declining concentration, while the EMA/HMPC classifies it under traditional use for symptoms of asthenia. Despite broad evidence, the overall rating is B (Strong) rather than A because the evidence is fragmented across numerous indications without reaching definitive strength in any single condition, and many trials are of moderate quality with small sample sizes.

Stinging nettle leaf/herb is approved by Commission E and ESCOP for adjuvant treatment of rheumatic and arthritic conditions and as a diuretic for urinary tract inflammation. It acts through NF-kB inhibition, COX-1/2 inhibition, and H1-receptor antagonism. The Mittman (1990) study provided initial evidence for allergic rhinitis, and in vitro work shows multi-target anti-allergic mechanisms. The herb is distinct from nettle root (used for BPH) and should not be confused with it. Safety profile is excellent with minimal side effects.

Turmeric is approved in Europe as a traditional medicine for mild digestive complaints. Curcumin, its principal active compound, has potent anti-inflammatory and antioxidant activity in vitro but notoriously poor oral bioavailability. This has spawned a generation of enhanced formulations (Meriva, Longvida, Theracurmin) that dramatically improve absorption. Clinical evidence is most promising for osteoarthritis pain, with emerging data for IBD and metabolic syndrome. A rare but real hepatotoxicity signal has emerged, linked to the HLA-B*35:01 allele.